Ropivacaine, a new local anaesthetic agent, has been demonstrated to have less potential than bupivacaine for central nervous system toxicity on the basis of human and animal studies. We report a case of a convulsion secondary to presumed inadvertent intravascular injection of 20 mg of ropivacaine in a 44 kg patient during an epidural for chronic pain. There were minimal signs of cardiovascular toxicity.
The recently introduced amide local anaesthetic agent ropivacaine has been demonstrated by many studies to be both safe and effective via the epidural route [1] [2] [3] . The central nervous system toxicity of the drug is thought to be lower than bupivacaine [4] [5] [6] . We report a patient who developed a generalized grand mal seizure following the injection of 20 mg of ropivacaine through an 18 gauge Tuohy epidural needle 7 .
CASE HISTORY
A thirteen-year-old male patient with chronic pain secondary to bladder spasm was referred for an epidural infusion of local anaesthetic. The past history included cerebral palsy with resulting spastic quadraparesis, urological problems relating to bladder instability and sphincteric dysfunction and severe kyphoscoliosis. He had required several corrective orthopaedic procedures including a varus rotating pelvic osteotomy. He was of normal intellect and had no previous history of epilepsy. The patient had a six-year history of chronic pain in the supra-pubic region with spasmodic inguinal and scrotal radiation. Urodynamic studies had initially showed sphincter and detrusor inco-ordination and a vesicostomy had been performed with only temporary relief of his symptoms. Antispasmodics and benzodiazepines had been prescribed with only brief periods of improvement.
Routine maintenance medication included baclofen 10 mg once daily, imipramine 25 mg twice daily, and diazepam 2.5 mg four times daily. There was a history of an allergic reaction to sulphonamides, but no adverse reaction had been reported with previous general or regional anaesthesia. His body weight was 44 kg.
The procedure was undertaken in an anaesthetic room of the operating theatre. No premedication was employed apart from EMLA cream applied topically to the dorsum of each hand. Intravenous access was secured with a 20 gauge cannula, and a sphygmomanometer was used for measuring blood pressure. The heart rate was 106 beats/min and the blood pressure was 100/60 mmHg at the start of the procedure.
The patient was placed in the left lateral position and the skin prepared with chlorhexidine in alcohol. The interspace between the twelfth thoracic and the first lumbar vertebral spines was identified and a skin weal raised using procaine as the local anaesthetic. The epidural space was located using the loss of resistance to air technique with an 18 gauge Tuohy needle.
After confirming that no CSF or blood could be withdrawn from the Tuohy needle, 2 ml of ropivacaine HCl (10mg/ml) was injected through the needle over approximately fifteen seconds. The patient immediately asked whether his "face should be feeling different". Within one minute a classical grand mal seizure ensued.
Resuscitation was immediately commenced with oxygen via a bag and mask, and midazolam 1 mg IV was administered. The convulsion lasted for two minutes after which an ECG monitor and pulse oximeter were attached to the patient. The heart rate was 160/min, O 2 saturation 97%, and the blood pressure 90/60 mmHg. The patient was then transferred to the recovery area for further observation and a 12lead ECG performed at this time demonstrated a sinus tachycardia with an intraventricular conduction defect.
The patient's state of consciousness recovered to normal over the next fifteen minutes. There were no further adverse sequelae. A blood sample was taken from an antecubital vein between 30 and 40 minutes after the fit for determination of the serum ropivacaine level. A serum sample was spun and frozen and kept at -20°C until the specimen was assayed. The serum ropivacaine concentration was determined by solvent extraction followed by gas chromatography-(SIM) mass spectrometry. The concentration of ropivacaine in the sample taken was 1.4 mg/l.
The following day an unsuccessful attempt was made to repeat the procedure at two different interspaces. This resulted in three bloody taps at these interspaces and raised the possibility of an unusually vascular epidural space.
DISCUSSION
Ropivacaine has recently been introduced into clinical anaesthesia as a potential substitute for bupivacaine. On the basis of human 3 and animal studies 6 ropivacaine is likely to be associated with less central nervous system toxicity at equipotent doses when compared with bupivacaine. The recommended "safe" dosage in humans has not been established for ropivacaine, given the ethical problems associated with infusing local anaesthetic to levels where it may cause seizures. In the past these recommendations have been inferred from case reports or extrapolated from animal studies to man. The product insert advocates a test dose containing "3-5 ml of local anaesthetic solution, preferably containing 5 µg/ml adrenaline (e.g. 3 ml lignocaine 2.0% with adrenaline 1: 200,000)". The recommended total dose of ropivacaine should not exceed 200 mg (Astra-Naropin product information). In the event of inadvertent intravascular injection the tachycardia from adrenaline is not always reliable, and verbal contact should be maintained to ascertain the early onset of central nervous system toxicity. The plasma level of 1.4 mg/l reported here would certainly have been consistent with inadvertent intravascular injection. The plasma level at the time of the seizure would have been much higher (6 to 30 mg/l) (L. E. Mather, personal communication), given the time to sampling. Ropivacaine has a relatively high plasma clearance (0.82±0.16 litre/min) in adults 8 . In human studies symptoms of toxicity occurred at plasma concentrations between 1 and 2 mg/l upon intravenous infusion 3 .
Several factors may have altered the seizure threshold in our patient including the concomitant use of other drugs. Maintenance therapy with baclofen, a GABA derivative, might be expected to lower the threshold for seizures in susceptible individuals 9 . However the patient was also on diazepam which could be expected to raise the threshold for seizures.
The total dose administered was only 20 mg ropivacaine. This remains a very low dose to produce seizures and there is no prior report of such a dose contributing to facial numbness or fitting in humans. The rapid onset of fitting following the onset of facial numbness demonstrates the close relationship between this symptom and major toxicity, as would be expected from intravascular administration 10 .
Our experience suggests that the rate of injection of ropivacaine to be administered via the epidural route as the main dose should be reduced below that recommended in the product insert. The basic safety precautions of slow injection and pausing to wait for any adverse effect remain important safeguards against systemic toxicity.
